Peginterferon beta-1a (Plegridy) for multiple sclerosis.
The Medical letter on drugs and therapeutics
View on PubMed
Abstract & Figures
Pegylated interferon beta-1a (Plegridy) injected subcutaneously every 2 weeks appears to be similar in its efficacy and adverse effects to older interferon formulations that must be injected more frequently.
Figures and Tables
Sorry, we couldn't extract any figures or tables for this paper.
Sorry, we couldn't extract any citations for this paper.
Sorry, we couldn't extract any references for this paper.
Loading similar papers…
Slides referencing similar topics
Stephen Jay Gould • Feb 10, 2018
Mar 12, 2015
Lecture 1a: administration
Trevor Cohn • Sep 18, 2015